Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.34 |
| ▸ | GCGR | P47871 | 4/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29314661 | 0.91 | CFTR (0.40) | BACE1BACE2MAPTNAMPT | |
| SCHEMBL29314664 | 0.91 | SCN9A (0.39) | SCN10ASCN9A | |
| SCHEMBL23037521 | 0.90 | NAMPT (0.37) | MAPTNAMPTSCN9A | |
| SCHEMBL30539908 | 0.90 | NAMPT (0.37) | MAPTNAMPTSCN9A | |
| SCHEMBL29314678 | 0.89 | MAOB (0.38) | MAPTGCGRNAMPT | |
| SCHEMBL29314715 | 0.88 | MAPT (0.36) | MAPTKLKB1NAMPT | |
| SCHEMBL29314658 | 0.88 | KLKB1 (0.36) | MAPTKLKB1 | |
| SCHEMBL29314666 | 0.86 | EGLN1 (0.35) | BACE1BACE2MAPTNAMPTSCN9A | |
| SCHEMBL29314760 | 0.85 | NAMPT (0.36) | MAPTNAMPT | |
| SCHEMBL26783893 | 0.85 | CFTR (0.40) | BACE1BACE2MAPTGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | BACE1 406/4885BACE2 1496/4885MAPT 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.